

STANDARD MEDICARE PART B MANAGEMENT

LUPRON DEPOT 1-Month 7.5 mg
LUPRON DEPOT 3-Month 22.5 mg
LUPRON DEPOT 4-Month 30 mg
LUPRON DEPOT 6-Month 45 mg
(leuprolide acetate for depot suspension)

leuprolide acetate depot 3-month 22.5 mg

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Lupron Depot 1-Month 7.5 mg, Lupron Depot 3-Month 22.5 mg, leuprolide acetate depot 3-month 22.5 mg, Lupron Depot 4-Month 30 mg, and Lupron Depot 6-Month 45 mg are indicated in the treatment of advanced prostatic cancer.

B. Compendial Uses

1. Prostate cancer³
2. Ovarian Cancer - Malignant sex cord-stromal tumors
3. Gender dysphoria (also known as transgender and gender diverse (TGD) persons)
4. Induction of amenorrhea
5. Catamenial pneumothorax
6. Irritable bowel syndrome

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. CRITERIA FOR INITIAL APPROVAL

A. Prostate cancer

Authorization of 12 months may be granted for treatment of prostate cancer.

B. Gender dysphoria

1. Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member when all of the following criteria are met:

leuprolide depot-Lupron Depot Prostate Cancer 4694-A MedB CMS P2023a.docx© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- a. The member has a diagnosis of gender dysphoria.
- b. The member has reached Tanner stage 2 of puberty or greater.
- 2. Authorization of 12 months may be granted for gender transition when all of the following criteria are met:
 - a. The member has a diagnosis of gender dysphoria.
 - b. The member will receive the requested medication concomitantly with gender-affirming hormones.

C. Ovarian cancer

Authorization of 12 months may be granted for treatment of malignant sex cord-stromal tumors.

D. Induction of amenorrhea

Authorization of 6 months may be granted for the induction of amenorrhea prior to undergoing bone marrow transplantation.

E. Catamenial pneumothorax

Authorization of 3 months may be granted for treatment of catamenial pneumothorax.

F. Irritable bowel syndrome

Authorization of 6 months may be granted for treatment of irritable bowel syndrome.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested medication.

- A. Authorization for 12 months may be granted when all of the following criteria are met:
 - 1. The member is currently receiving therapy with the requested medication.
 - 2. The requested medication is being used to treat ovarian cancer.
 - 3. The member is receiving benefit from therapy and has not experienced unacceptable toxicity.
- B. Authorization for 12 months may be granted when all of the following criteria are met:
 - 1. The member is currently receiving therapy with the requested medication.
 - 2. The requested medication is being used to treat prostate cancer.
 - 3. The member is receiving benefit from therapy (e.g., serum testosterone less than 50 ng/dL) and has not experienced unacceptable toxicity.
- C. Authorization for 12 months may be granted when all of the following criteria are met:
 - 1. The member is currently receiving therapy with the requested medication.
 - 2. The requested medication is being used to treat gender dysphoria
 - 3. The member is receiving benefit from therapy.
- D. Authorization for 6 months may be granted when all of the following criteria are met:
 - 1. The member is currently receiving therapy with the requested medication.
 - 2. The requested medication is being used to induce amenorrhea or to treat catamenial pneumothorax or irritable bowel syndrome.
 - 3. The member is receiving benefit from therapy.

IV. SUMMARY OF EVIDENCE

The contents of this policy were created after examining the following resources:

1. The prescribing information for Lupron Depot 7.5 mg, 22.5 mg, 30 mg, 45 mg, and leuprolide acetate 22.5 mg.
2. The available compendium
 - a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - b. Micromedex DrugDex
 - c. American Hospital Formulary Service- Drug Information (AHFS-DI)
 - d. Lexi-Drugs
 - e. Clinical Pharmacology
3. NCCN Guideline: Prostate cancer

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Lupron Depot 7.5 mg, 22.5 mg, 30 mg, 45 mg, and leuprolide acetate 22.5 mg are covered in addition to the following:

1. Prostate cancer
2. Ovarian Cancer - Malignant sex cord-stromal tumors
3. Gender dysphoria (also known as transgender and gender diverse (TGD) persons)
4. Induction of amenorrhea
5. Catamenial pneumothorax
6. Irritable bowel syndrome

V. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

Support for using Lupron Depot to treat malignant sex cord-stromal tumors and prostate cancer can be found in the NCCN Drugs and Biologics Compendium. Use of information in the NCCN Drugs and Biologics Compendium for off-label use of drugs and biologicals in an anti-cancer chemotherapeutic regimen is supported by the Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 (Off-Label Use of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen).

Support for using Lupron Depot for gender dysphoria can be found in the Endocrine Society Clinical Practice guideline for endocrine treatment of gender-dysphoric/gender-incongruent persons. The guidelines support GnRH agonist use in both transgender males and transgender females. Specific products are not listed; therefore, coverage is applied to the entire class of GnRH agonists.

Support for using Lupron Depot for gender dysphoria can also be found in the World Professional Association for Transgender Health (WPATH). According to the Standards of Care for the Health of Transgender and Gender Diverse People, Version 8, prescribing GnRH agonists to suppress sex steroids without concomitant sex steroid hormone replacement in eligible transgender and gender diverse adolescents seeking such intervention who are well into or have completed pubertal development (defined as past Tanner stage 3) but are unsure about or do not wish to begin sex steroid hormone therapy. WPATH also recommends beginning pubertal hormone suppression in eligible transgender and gender diverse adolescents after they first exhibit physical changes of puberty (Tanner stage 2).

WPATH recommends health care professionals prescribe progestins or a GnRH agonist for eligible transgender and gender diverse adolescents with a uterus to reduce dysphoria caused by their menstrual cycle when gender-affirming testosterone use is not yet indicated.

WPATH also recommends health care professionals prescribe testosterone-lowering medications (including GnRH agonists) for eligible transgender and gender diverse people with testes taking estrogen as part of a hormonal treatment plan if their individual goal is to approximate levels of circulating sex hormone in cisgender women.

leuprolide depot-Lupron Depot Prostate Cancer 4694-A MedB CMS P2023a.docx© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Support for using Lupron Depot to induce amenorrhea can be found in a study by Laufer and colleagues. Leuprolide was an effective way of inducing amenorrhea prior to women undergoing bone marrow transplantation. In 10 women, leuprolide 7.5 mg IM was given every 28 days before bone marrow transplantation and continued until the platelet count was greater than 50,000. Nine of the 10 women experienced amenorrhea. One woman with an "18-week" sized uterus containing a submucous myoma had continued spotting.

Support for using Lupron Depot to treat catamenial pneumothorax can be found in a case study published by Garris and Sokol. A 35-year-old nulligravida black female diagnosed with catamenial pneumothorax was successfully treated with depot leuprolide 7.5 mg monthly for 3 months followed by 3.75 mg monthly for 3 months. Prior to leuprolide treatment, the patient had undergone a right partial pleurectomy and partial right upper lobectomy without resolution of her catamenial respiratory symptoms. With leuprolide treatment, her symptoms resolved without recurrence in 2 years of followup. Because of severe vasomotor and emotional side effects which developed with leuprolide therapy, daily doses of continuous conjugated estrogens of 0.625 mg and medroxyprogesterone acetate 2.5 mg were instituted as a hormonal add-back regimen without apparent exacerbation of respiratory symptoms.

Support for using Lupron Depot to treat irritable bowel syndrome can be found in a study by Mathias et al. In a multicenter, double-blind study, women receiving leuprolide depot 7.5 mg monthly had improved abdominal pain and nausea as compared with placebo. Female patients with functional bowel disease were randomized to receive monthly intramuscular injections of either leuprolide 3.75 mg (n=32), leuprolide 7.5 mg (n=33), or placebo (n=35) for 16 weeks. Total symptom scores (pain, nausea, vomiting, bloating, anorexia, early satiety, altered bowel habits) were not statistically different for the leuprolide group compared with the placebo group. However, scores for pain and nausea for the leuprolide 7.5 mg group were significantly better than placebo at 16 weeks (p=0.044 and p less than 0.001, respectively). In both leuprolide groups, patient evaluations and physician global evaluations were statistically better (p less than 0.001).

VI. REFERENCES

1. Lupron Depot 7.5 mg, 22.5 mg, 30 mg, 45mg [package insert]. North Chicago, IL: AbbVie Inc.; April 2022.
2. Leuprolide acetate depot 22.5mg [package insert]. Warren, NJ: Cipla USA, Inc.; August 2018.
3. The NCCN Drugs & Biologics Compendium® © 2023 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 6, 2023.
4. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869–3903.
5. Gender Identity Research and Education Society. Guidance for GPs and other clinicians on the treatment of gender variant people. UK Department of Health. Published March 10, 2008.
6. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, 8th version. ©2022 World Professional Association for Transgender Health. Available at <http://www.wpath.org>.
7. DRUGDEX® System (electronic version). Truven Health Analytics, Ann Arbor, MI. Available at <http://www.micromedexsolutions.com>. Accessed February 7, 2023.
8. Laufer MR, Townsend NL, Parsons KE, et al: Inducing amenorrhea during bone marrow transplantation: a pilot study of leuprolide acetate. *J Reprod Med* 1997; 42(9):537-541.
9. Garris PD & Sokol MS: Leuprolide acetate treatment of catamenial pneumothorax. *Fertil Steril* 1994; 61:173-174.
10. Mathias JR, Clench MH, Abell TL, et al: Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. *Dig Dis Sci* 1998; 43(6):1347-1355.